

Supplementary Table 2. Baseline characteristics at initiation of b/tsDMARDs (3-year follow-up)

Variable	Total (n = 1,281)	ADA (n = 319)	ETN (n = 358)	IFX (n = 137)	ABT (n = 115)	TCZ (n = 246)	TOF (n = 106)	p value
Age (yr)	56.0 (45.0–63.0)	53.0 (43.0–61.0)	57.0 (46.0–64.0)	56.0 (49.0–62.0)	60.0 (52.5–68.5)	56.0 (44.0–63.0)	56.0 (45.0–65.0)	< 0.001
Sex, female	1,100 (85.9)	271 (85.0)	304 (84.9)	120 (87.6)	106 (92.2)	206 (83.7)	93 (87.7)	0.325
RA disease duration (yr)	8.0 (3.0–16.0)	7.0 (3.0–15.0)	9.0 (3.0–17.0)	8.0 (3.0–15.0)	10.0 (3.0–18.0)	7.0 (3.0–14.0)	11.0 (6.0–18.0)	0.022
RF positivity	1,210 (94.5)	294 (92.2)	339 (94.7)	129 (94.2)	112 (97.4)	233 (94.7)	103 (97.2)	0.246
Anti-CCP positivity	1,188 (92.7)	297 (93.1)	328 (91.6)	131 (95.6)	102 (88.7)	231 (93.9)	99 (93.4)	0.329
CCI	3.0 (2.0–4.0)	3.0 (2.0–4.0)	3.0 (2.0–4.0)	3.0 (2.0–4.0)	4.0 (3.0–5.0)	3.0 (2.0–4.0)	2.0 (1.0–3.0)	< 0.001
csDMARDs combination	1,201 (93.8)	307 (96.2)	331 (92.5)	136 (99.3)	110 (95.7)	227 (92.3)	90 (84.9)	< 0.001
MTX combination	1,122 (87.6)	301 (94.4)	316 (88.3)	135 (98.5)	81 (70.4)	206 (83.7)	83 (78.3)	< 0.001
Corticosteroid combination	1,119 (87.4)	280 (87.8)	316 (88.3)	120 (87.6)	92 (80.0)	220 (89.4)	91 (85.8)	0.211
ESR (mm/h)	47.0 (32.0–67.0)	51.0 (37.0–70.5)	56.0 (40.0–77.0)	44.0 (35.0–67.0)	36.0 (21.5–54.5)	45.5 (29.0–59.0)	28.0 (15.0–45.0)	< 0.001
CRP (mg/dL)	1.3 (0.5–2.7)	1.3 (0.5–2.7)	1.6 (0.7–3.2)	1.3 (0.6–2.7)	0.6 (0.1–1.7)	1.2 (0.5–2.6)	1.0 (0.3–1.7)	< 0.001
Previous use of b/tsDMARDs								< 0.001
0	824 (64.3)	248 (77.7)	241 (67.3)	111 (81.0)	71 (61.7)	116 (47.2)	37 (34.9)	
1	315 (24.6)	65 (20.4)	97 (27.1)	15 (10.9)	24 (20.9)	84 (34.1)	30 (28.3)	
≥ 2	142 (11.1)	6 (1.9)	20 (5.6)	11 (8.0)	20 (17.4)	46 (18.7)	39 (36.8)	
Starting year of b/tsDMARDs								< 0.001
2008–2014	847 (66.1)	268 (84.0)	324 (90.5)	104 (75.9)	41 (35.7)	110 (44.7)	0 (0.0)	
≥ 2015	434 (33.9)	51 (16.0)	34 (9.5)	33 (24.1)	74 (64.3)	136 (55.3)	106 (100.0)	

Values are presented as median (interquartile range) or number (%).

b/tsDMARDs, biological or targeted synthetic disease-modifying anti-rheumatic drugs; ADA, adalimumab; ETN, etanercept; IFX, infliximab; ABT, abatacept; TCZ, tocilizumab; TOF, tofacitinib; RA, rheumatoid arthritis; RF, rheumatoid factor; CCP, cyclic citrullinated peptide; CCI, Charlson comorbidity index; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; MTX, methotrexate; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.